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Enhancement of virus infectivity after sCD4 treatment has been documented for SIVagm and HIV-2. It
has been suggested that a similar phenomenon may play a role in HIV-1 infection. In the present study
we have analysed biological activities of virus neutralizing polyclonal and monoclonal human antibodies
and of sCD4, towards HIV-1 chimeras with envelope proteins derived from one donor, which display
different biological phenotypes. The antibodies, which recognize the V3 and/or the CD4 binding
domains of the glycoproteins of these viruses and also sCD4 showed different levels of virus neutralizing
activity toward the syncytium inducing HIV-1 strains. In contrast, they all dramatically enhanced the
infectivity of an HIV-l chimera with an envelope glycoprotein displaying the non-syncytium-inducing
phenotype. Given the relatively conserved nature of non-syncytium-inducing HIV-1 surface glycopro-
teins early after infection, these data suggest a major role for antibody mediated enhancement of virus
infectivity in the early pathogenesis of HIV-1 infection.
Professor Dr A. D. M. E. Osterhaus, Erasmus University Rotterdam. Institute of Virology, Dr
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INTRODUCTION
The identification and characterization of virus neutralization
inducing (VNI) antigenic sites on the glycoproteins of HIV-1
have been the focus of many studies (for review see [1]). For
practical reasons. HIV-I strains and primary HIV-I isolates
which efficiently replicate in T cells have predominantly been
used to study virus neutralization [1]. In this context it is
important to note that macrophage-tropic non-syncytium-
inducing (NSI) variants with low efficiency of replication in T
cells predominate in the asymptomatic stage and T cell line-
tropic syncytium inducing (Sl) variants are almost exclusively
found in late stages of the infection [2, 3]. The macrophage-
tropic NSI strains have been shown to exhibit a relatively
high level of conservation in their VNI V3 loop [4]. It has been
suggested that escape from virus neutralizing (VN) antibodies
is based on the relatively high mutation rate generally
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observed in the virus envelope glycoprotein. Given the fact
that also the CD4 binding domain (bd) is relatively conserved,
another mechanism of escape from VN antibodies may be
postulated for the relative success of NSI/macrophage-
tropic viruses to persist in the host. To study the basis of this
apparent paradox, we have used an env complementation
assay in which the biological activities could be compared of
human HIV-l-specific monoclonal and potyclonal antibody
preparations towards identical HIV-1 strains only differing
in their glycoproteins which displayed an SI or an NSI
phenotype.
MATERIALS AND METHODS
Human anrihadies, sCD4 and HIV-I envelope glycaproteins. The
human monoclonal antibodies (HuMoAbs) used are directed against
the CD4 binding domain (GP13 and GP68 [5]). a highly conserved
conformational epitope on gp4l {K14 [6]) and the HIV-I gpl20 V3
loop (257-D [7]). Furthermore sCD4 (kindly provided by Dr I. Jones
through the MRC AIDS directed programme) and HIVIG |8])
(kindly provided by Dr H. Schuiiemaker) were used as VN agents.
The env genes used 116.1 (SI), 16.2 (SI), 16.4 (NSI). MN and IIIB] for
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the production of envelope glycoproteitis in the capture antibody
ELISA and for the production of chimeric viruses have previously
been characterized and described [9, 10-12].
Capture (inlihody ELISA for mea.suremcnt nf relative affinity. The
relative affinity of the HuMoAbs used in the present study was
determined in a previously described ELISA. In short, ELISA plates
(Costar. Cambridge. MA 02140. USA. cat. no. 3590), coated with
affinity purified sheep immunoglobulins directed against the carboxy
terminus of gpl20 (Aalto BioReagents. Dublin. Ireland, cat. no.
D7324), were incubated for 2h with cell lysate of recombinant
vaccinia virus (rVV) infected HELA [13] cells (16 (NSI) and 16
(SD) or H!V-I infected SupTl [14] cells (MN [11] and IIIB [12]).
Plates were subsequently washed and incubated with serial dilutions
of previously described HuMoAbs (GP13. GP68 [5] and 257-D [7]).
The ELISA was completed and read as previously described [10].
The relative amount of antigen bound to the ELISA plates was
calibrated by using the same ELISA protocol with serial dilutions of
the antigen and a standard excess concentration of polyclonal serum
from seropositive individuals. The data presented are the mean
values of duplicates in one assay which was performed at least
twice with similar results.
Envelope traus-complementution assuy. This assay was based on a
previously described n««,v-complementation assay in which an env-
defective HIV-l provirus, encoding the bacterial CAT reporter gene
[15]. was complemented for a single round of replication by a set of
recently described HIV-1 envelope glycoproteins [9]. The env genes
encoding these glycoproteins were derived from biologically cloned
Sl or NSI viruses, isolated from one single donor (number 16) at a
single point in time in natural target cells (peripheral blood mono-
nuclear cells [PBMC]). in the complementation assay the genes
encoding these envelope glycoproteins were co-transfected into a
CD4~ cell line (COS [16]) together with the env-defective molecular
clone of the HIV-I IIIB strain. This resulted in the production of
virions carrying heterologous envelope glycoproteins which could
infect CD4^ cells, like the SupTI cells or PHA stimulated PBMC
used in this study. After 3 days cell free supernatants were collected
Table I. Relative affinities of HuMoAbs for different HIV-1
envelope glycoproteins
HuMoAb
KI4
GPU
GP68
257-D
Specificity
gp4I
CD4bd
CD4bd
V3 domain
16.1
(SI)
83*
83
67
125
HIV-1
16.2
(Sl)
67
83
67
125
strain (phenotype)
16.4
(NSI)
67
33
67
125
MN
(SI)
33
250
125
125
lllB
(SI)
67
250
250
_t
* Reciprocal ofdilutions of MoAbs, starting at 1 ^g/ml, still giving
50% of maximal binding with the respective envelope glycoproteins
in a capture antibody ELISA as a measure of relative affinity. The
data presented are the mean values of duplicates in one assay which
was performed at least twice with similar results.
t No binding: OD450nm values remained at background levels at
the concentrations tested.
by centrifugation and frozen at — I35''C. For infection the amount
of p24 antigen, as determined with a p24 ELISA kit (V5. Organon
Teknika. Boxtel. The Netherlands) was calibrated and the level of
envelope expression was checked with the capture antibody ELISA
(see above). Infection was performed overnight at 37'C in 1ml
medium. After 24 h the cells were washed and cultured for 72 h.
CAT activity in these cells was measured in a previously described
CAT assay using a two-phase extraction system [17]. CAT activities
expressed in the cells were considered a direct measure of virus
infectivity in these assays.
R E S U L T S
Relative affinity of HuMoAbs for HIV-I envelope
glycoproteins
The HuMoAbs used in these experiments were selected on
basis of their epitope specificities and relative affinities in the
capture antibody ELISA for different HIV-I envelope glyco-
proteins (Table 1). The same reeombinant envelope glyco-
proteins were used in the env complementation assay (Table
2). Both CD4 bd specific HuMoAbs GP13 and GP68 showed
an overall higher relative affinity for the glycoproteins of the
T eell line adapted HlV-1 strains IIIB atid MN than for the
glycoproteins derived from the donor number 16 HIV-1
strains. The V3 loop specific HuMoAb 257-D showed a
high relative affinity for the glycoproteins of the MN-like
HIV-I strains and no binding was observed in this ELISA
with the glycoproteins of HIV-1 IIIB (Table 1).
Virus neutralization and enhancement of viral infectivity by
sCD4 and human antibodies
The VN activities of human antibodies and sCD4 toward T
cell line adapted strains HIV-1 MN and HIV-1 IIIB(Tabte2)
have been documented previously [10-13]. The CD4 bd
specific HuMoAbs GP13 and GP68 as well as HIVIG and
sCD4. inhibited infectivity of HIV-1 16.2 (SI) only to a
limited extent (< 50%) when tested at a concentration
(l5/(g/ml) that significantly inhibited infectivity of HIV-1
IIIB in the env complementation assay (reduction to 15%,
12%, 9% and 8% respectively) (Table 2). The V3 domain
specific HuMoAb tested at the same concentration, neutral-
ized HIV-1 16.2 (SI), as was shown by a reduction of CAT
activities to 0.7% (Table 2). No major biological activity of
any of the antibodies tested or sCD4, was observed against
HIV-1 16.1 (SI) as was shown by a reduction of CAT activity
with 2-9% only, using 15//g/ml antibody (Table 2).
In contrast to the VN activities observed with the SI
viruses, the same concentration of ail these VN antibodies
and sCD4 caused a dramatic enhancement of infectivity of
HIV-1 16.4 which has a NSI envelope (> six-fold increase in
CAT activity) (Table 2). In order to demonstrate the dose
dependency of these phenomena, dose response curves were
made with the V3 domain specific HuMoAb 257-D, which
exhibited the highest affinity for all the envelop proteins
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Table 2. Virus neutralizing and enhancement activities of human antibody preparations and sCD4
Virus strain (biological phenotype)
Antibody preparation Epitope
gp41
CD4bd
CD4bd
CD4bd
V3
DOhr
MN*
(SI)
_ t
-
H-
H-
H-
+
IIIB
(SI)
-
+
+
+
-
+
IIIB
(SI)
I00§
72.461*
103
15
12
9
97
8
16.1
(SI)
100
55.065
98
97
93
92
91
95
16.2
(SI)
100
54.428
106
65
65
84
0.7
95
16.4
(NSI)
100
8.239
96
732
741
620
655
744
none
KI4
GP13
GP68
sCD4
257-D
HIVIG
VN assay env complementation assay
X Due to differences in the VN assays used, biological activities are indicated as high ( +) or undetectable ( - ).
§ Percentage of CAT activity relative to the CAT activity observed in the absence of antibody. The mean value
within one experiment obtained with SupTl cells is given. The antibody preparations were tested at least twice
with the same chimeric virus yielding similar results.
*CAT activity in counts per minute (cpm), background values range from 300 to 800cpm.
tested (Table 1). Clear dose related VN and enhancement
activities were found with this antibody in the env comple-
mentation assay with HIV-I 16.2 (SI) and HIV-1 16,4 (NSI)
respectively (Fig. I). When these experiments were repeated
in PHA stimulated PBMC essentially the same phenomena
were observed. The overall differences were however less
pronounced in this system (average enhancement about
50%) probably due to a limited cellular host range of this
virus (A. C. Andeweg et al, unpublished observations).
DISCUSSION
Using an assay that is highly sensitive for measuring viral
entry we have shown in the present study that both sCD4 and
human antibodies which neutralize SI HIV-1 strains may
enhance infectivity of NSI HIV-1 strains.
HIVIG, sCD4 and the CD4 bd specific HuMoAbs GPI3
and GP68 readily neutralized the HIV-1 IIIB strain whereas
limited or no VN activity was observed against the primary
HIV-I strains from donor number 16. This supports previous
observations that sCD4, CD4 bd specific HuMoAbs and
HIVIG have little or no neutralizing activity against primary
virus strains (M. Schutten. personal observation and [18]). It
has been shown by several groups that VN capacity of V3
loop specific MoAbs toward T cell line adapted HIV-1 strains
is dependent on the affinity of the antibody for the V3 loop of
the HIV-1 strain used [7, 19]. However, in the present
study we showed that VN activity of V3 loop specific
HuMoAb 257-D toward the SI HIV-1 strains from donor
number 16 is not directly related to its relative affinity for the
glycoproteins involved: identical relative affinities for the 16.1
(SI) and 16.2 (SI) envelope glycoproteins were observed, but
reductions in the env complementation assay proved to be 9
and 99.3% respectively. This was unexpected since both
envelopes exhibit SI capacity and a 95% overall predicted
amino acid sequence homology exists between these envel-
opes [9]. Since we have previously shown that other domains
than the V3 domain are involved in membrane fusion [10]. it
may be speculated that HIV-1 16.1 is less dependent on the
V3 domain to establish membrane fusion and infection.
The efficiency of entry into T cell lines of the NS! HIV-1
strain 16.4 was significantly lower than that of the SI HIV-1
strains 16.1 and 16.2 as shown by a > six-fold lower CAT
activity. The infectivity of the NSI HIV-I strain was however
enhanced to levels comparable to those of the SI HlV-1
strains by the administration of sCD4 or antibodies that
neutralized these SI HlV-1 strains. Different mechanisms
for HIV-1 specific antibody mediated enhancement have
been described, including Fc receptor- and complement-
mediated enhancement [20, 21]. Two observations argue
against the same mechanism in our experiments. Firstly,
SupTl cells do not express Fc receptors [14] and complement
was not present in the assays. Secondly, enhancement of HIV-
I 16.4 (NSI) was also observed with sCD4 (Table 2). An
explanation for the observed enhancement can be found in a
mechanism previously described for the enhancement of non-
cytopathic SIV agm infectivity and induction of HIV-2
mediated cell fusion of CD4' cells, by sCD4. In these systems
sCD4 does not induce dissociation of surface glycoprotein
(SU) from infected cells [22, 23]. In contrast, sCD4 does
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Fig. 1. Virus neutralizing and infectivity enhancing activities of
serial dilutions of HuMoAb 257-D using SupTI cells in the env
complementation assay with HIV-l 16.1 (SI), HIV-l 16.2 (SI) and
HIV-l 16,4 (NSI) chimeric viruses. Counts per min (cpm) obtained
in the assays with aniibodies, are expressed as percentages of cpm
obtained in the assay carried out in the absence of antibodies.
Dotted line represents 50% inhibition of virus infectivity.
induce dissociation of SU from cells infected with T cell line
adapted HIV-l strains which are readily neutralized by sCD4
[24]. We hypothesize that both sCD4 and the antibodies we
studied, cause conformational changes in the viral envelope
complex of certain NSI/macrophage-tropic HIV-l strains
exposing cryptic fusion sites as was also shown in the
SlVagm and HIV-2 systems [22, 23]. These changes would
allow a more efficient virus-cell fusion that is less dependent
on the presence of CD4 on the target cell membrane.
Taken together our data suggest that naturally occurring
antibodies to the so-called HIV-l VNI antigenic sites, may
cause either neutralization or enhancement dependent on the
biological phenotype of the virus recognized. If indeed our
findings are a reflection of a more general phenomenon of
enhancement also found in infections with other lentiviruses
like HlV-2 (23] and SIVagm [22], they may explain why early
after HIV-l infection predominantly viruses with an NSI/
macrophage-tropic phenotype are found and why these
viruses are able to persist in the infected host despite the
conserved nature of their 'VNI' antigenic sites. The observed
enhancement would actually favour replication of viruses
displaying the NSI/macrophage-tropic phenotype, whereas
viruses displaying the SI/T cell line-tropic phenotype are
neutralized.
These observations may not only have implications for our
understanding of the pathogenesis of HIV-l infection but
also for the development of immunization strategies. If this
observation is the reflection of a more general phenomenon,
the induction or administration of antibodies that neutralize
viruses of the SI/T cell-tropic phenotype, which is a com-
monly followed strategy at present, may actually be counter
productive.
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